文献速递心脑血管急症重症综合管理与镇静镇痛

C端精氨酸加压素前体与动脉瘤性蛛网膜下腔出血危重患者的疾病结局和死亡率相关,但与迟发性脑缺血无关:一项前瞻性队列研究

C-Terminal Proarginine Vasopressin is Associated with Disease Outcome and Mortality, but not with Delayed Cerebral Ischemia in Critically Ill Patients with an Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study.
PubMed 文献 · Neurocrit Care · 2022-06-25
一句话结论在aSAH危重患者中,入院CT-proAVP可预测1年不良功能结局和死亡,但对DCI预测能力低。

这项单中心前瞻性观察性队列研究纳入100例动脉瘤性蛛网膜下腔出血(aSAH)危重患者,入院时检测C端精氨酸加压素前体(CT-proAVP),评估其预测1年不良功能结局(Glasgow结局量表评分1-3)、30天和1年死亡率以及迟发性脑缺血(DCI)的能力,并与WFNS评分和APACHE IV模型比较。结果显示CT-proAVP对1年不良功能结局、30天死亡和1年死亡的AUC分别为0.84、0.84和0.79,对DCI的AUC为0.67。在多因素模型中,CT-proAVP≥24.9 pmol/L是不良功能结局的显著预测因子(OR 8.04),CT-proAVP≥29.1 pmol/L和≥27.7 pmol/L分别是30天和1年死亡率的显著预测因子(OR 9.31和5.15),但CT-proAVP≥29.5 pmol/L对DCI的预测未达统计学显著(p=0.061)。

要点

  • 在100例aSAH危重患者中,入院CT-proAVP中位数为24.9 pmol/L(IQR 11.5-53.8),45例1年功能结局不良,19例30天内死亡,25例1年内死亡,28例发生DCI。
  • CT-proAVP识别1年不良功能结局的AUC为0.84(95%CI 0.77-0.92,p<0.001),识别30天死亡的AUC为0.84(95%CI 0.76-0.93,p<0.001),识别1年死亡的AUC为0.79(95%CI 0.69-0.89,p<0.001)。
  • 调整WFNS和APACHE IV评分后,CT-proAVP≥24.9 pmol/L是不良1年功能结局的显著预测因子(OR 8.04,95%CI 2.97-21.75,p<0.001)。
  • 调整WFNS和APACHE IV评分后,CT-proAVP≥29.1 pmol/L是30天死亡的显著预测因子(OR 9.31,95%CI 1.55-56.07,p=0.015),CT-proAVP≥27.7 pmol/L是1年死亡的显著预测因子(OR 5.15,95%CI 1.48-17.93,p=0.010)。
  • CT-proAVP识别DCI的AUC较低,为0.67(95%CI 0.55-0.79,p=0.008);调整改良Fisher量表后,CT-proAVP≥29.5 pmol/L对DCI的预测未达统计学显著(p=0.061)。

适用人群与场景

  • 重症监护病房收治的动脉瘤性蛛网膜下腔出血(aSAH)危重患者。

诊断标准与关键阈值

  • 1年不良功能结局定义为Glasgow结局量表评分1-3分。
  • 迟发性脑缺血(DCI)按原文定义。

研究设计与关键结果

  • 研究类型:单中心、前瞻性、观察性队列研究;样本量100例;纳入aSAH危重患者;入院时检测CT-proAVP。
  • 主要终点:1年不良功能结局(Glasgow结局量表评分1-3分),在多因素logistic回归模型中调整WFNS和APACHE IV评分。
  • 关键结果:CT-proAVP识别1年不良功能结局的AUC为0.84(95%CI 0.77-0.92,p<0.001);识别30天死亡的AUC为0.84(95%CI 0.76-0.93,p<0.001);识别1年死亡的AUC为0.79(95%CI 0.69-0.89,p<0.001);识别DCI的AUC为0.67(95%CI 0.55-0.79,p=0.008)。
  • 多因素模型:调整WFNS和APACHE IV评分后,CT-proAVP≥24.9 pmol/L是不良1年功能结局的显著预测因子(OR 8.04,95%CI 2.97-21.75,p<0.001);CT-proAVP≥29.1 pmol/L是30天死亡的显著预测因子(OR 9.31,95%CI 1.55-56.07,p=0.015);CT-proAVP≥27.7 pmol/L是1年死亡的显著预测因子(OR 5.15,95%CI 1.48-17.93,p=0.010)。
  • DCI多因素模型:调整改良Fisher量表后,CT-proAVP≥29.5 pmol/L对DCI的预测未达统计学显著(p=0.061)。
  • 事件数:45例患者1年功能结局不良,19例30天内死亡,25例1年内死亡,28例发生DCI;CT-proAVP中位水平24.9 pmol/L(IQR 11.5-53.8)。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性、观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CT-proAVP能够预测aSAH危重患者的不良功能结局和死亡率,但其预测DCI的能力较低。

指南或共识出处

  • Nederlands Trial Register: NTR4118。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is an important indication for intensive care unit admission and may lead to significant morbidity and mortality. We assessed the ability of C-terminal proarginine vasopressin (CT-proAVP) to predict disease outcome, mortality, and delayed cerebral ischemia (DCI) in critically ill patients with aSAH compared with the World Federation of Neurological Surgeons (WFNS) score and Acute Physiological and Chronic Health Evaluation IV (APACHE IV) model.

METHODS: C-terminal proarginine vasopressin was collected on admission in this single-center, prospective, observational cohort study. The primary aim was to investigate the relationship between CT-proAVP and poor functional outcome at 1 year (Glasgow Outcome Scale score 1-3) in a multivariable logistic regression model adjusted for WFNS and APACHE IV scores. Secondary aims were mortality and DCI. The multivariable logistic regression model for DCI was also adjusted for the modified Fisher scale.

RESULTS: In 100 patients, the median CT-proAVP level was 24.9 pmol/L (interquartile range 11.5-53.8); 45 patients had a poor 1-year functional outcome, 19 patients died within 30 days, 25 patients died within 1 year, and DCI occurred in 28 patients. Receiver operating characteristics curves revealed high accuracy for CT-proAVP to identify patients with poor 1-year functional outcome (area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.77-0.92, p < 0.001), 30-day mortality (AUC 0.84, 95% CI 0.76-0.93, p < 0.001), and 1-year mortality (AUC 0.79, 95% CI 0.69-0.89, p < 0.001). CT-proAVP had a low AUC for identifying patients with DCI (AUC 0.67, 95% CI 0.55-0.79, p 0.008). CT-proAVP ≥ 24.9 pmo/L proved to be a significant predictor for poor 1-year functional outcome (odds ratio [OR] 8.04, 95% CI 2.97-21.75, p < 0.001), and CT-proAVP ≥ 29.1 pmol/L and ≥ 27.7 pmol/L were significant predictors for 30-day and 1-year mortality (OR 9.31, 95% CI 1.55-56.07, p 0.015 and OR 5.15, 95% CI 1.48-17.93, p 0.010) in multivariable models with WFNS and APACHE IV scores. CT-proAVP ≥ 29.5 pmol/L was not a significant predictor for DCI in a multivariable model adjusted for the modified Fisher scale (p = 0.061).

CONCLUSIONS: C-terminal proarginine vasopressin was able to predict poor functional outcome and mortality in critically ill patients with aSAH. Its prognostic ability to predict DCI was low.

TRIAL REGISTRATION: Nederlands Trial Register: NTR4118.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. van Oers JAH, Ramnarain D, Oldenbeuving A, et al. C-Terminal Proarginine Vasopressin is Associated with Disease Outcome and Mortality, but not with Delayed Cerebral Ischemia in Critically Ill Patients with an Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study. Neurocrit Care. 2022. PMID: 35750931. doi:10.1007/s12028-022-01540-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。